Navigation Links
Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
Date:5/15/2013

al risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the timing, progress and anticipated results of the clinical development of onapristone, Arno's use of the diagnostic test being developed with Clarient in its planned Phase I trial of onapristone, as well as Arno's strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of onapristone or any of our other product candidates, our ability to finance the development of our product candidates, regulatory risks, and our reliance on third party researchers and other collaborators. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2012. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

[i] National Cancer Institute. NCI Dictionary of Cancer Terms. Available at: http://www.cancer.gov/dictionary?cdrid=423248. Last accessed: May 7, 2013.

[ii] American Cance
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
(Date:7/10/2014)...  RESMED INC. (NYSE: RMD ) today announced ... ended June 30, 2014 results on Thursday, July 31, 2014, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
(Date:7/10/2014)... July 10, 2014  Decision Resources Group finds ... disease (ID) specialists are willing to prescribe Durata,s ... for use as OPAT, approximately two-thirds of the ... to their hospital inpatients. However, our findings indicate ... are initiated on OPAT following hospital discharge, and ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... is largely a collaborative enterprise. Frequently researchers from ... their efforts and exchange ideas, to devise new ... as those known as autism spectrum disorders, researchers ... diverse populations of patients, finding a broader pool ...
... AZOR Using 24-Hour Ambulatory BP MeasuresPARSIPPANY, N.J., May 8 ... at the American Society of Hypertension, Inc. (ASH) Twenty-Fourth ... Francisco from the AZ OR(R) T rial ... ontrol ( AZTEC ) demonstrated that a stepwise amlodipine ...
Cached Medicine Technology:Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 2Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 3Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 4New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 2New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 3New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 4New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 5New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 6New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 7New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 8New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure 9
(Date:7/11/2014)... research conducted at Aarhus University has revealed that people ... are only half as likely as their urban counterparts ... colitis and Crohn,s disease. The study findings have recently ... . , "It is extremely exciting that we can ... more classic inflammatory diseases appear to depend on the ...
(Date:7/11/2014)... July 11, 2014 As reported by ... For Cocaine: Are Genetics To Blame (6/30), Indino Downey ... cocaine and paraphernalia to smoke it with. His father, ... that his son inherited from him may have something ... made the news during the 1980s and 1990s for ...
(Date:7/11/2014)... Leeds, England (PRWEB) July 11, 2014 Having ... later as a member of mental hospital staff, Roger Grainger ... among medical professionals in his new book, “You Never Get ... 4 people in the United Kingdom will experience some kind ... , “Society still needs to take a look at ...
(Date:7/11/2014)... 11, 2014 AngelWeddingDress is now providing ... 2014 summer collections ”. When it comes to buying ... comes AngelWeddingDress with the unlimited stock of beautiful wedding ... for its wonderful summer wedding gowns. , The ... clients to keep pace with the newest fashion trends. ...
(Date:7/11/2014)... Seattle, WA (PRWEB) July 11, 2014 ... but the rate of return to play has not ... at the American Orthopaedic Society for Sports Medicine’s ( ... for NFL players is approximately 90 percent no matter ... study highlighted the success rate of return to play ...
Breaking Medicine News(10 mins):Health News:Growing up on a livestock farm halves the risk of inflammatory bowel diseases 2Health News:Roberty Downey's Son Arrested For Cocaine 2Health News:Psychiatric Hospital Patient and Registered Psychologist Explores Mental Health and Therapy in New Book "You Never Get Out" 2Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2
... July 14 Poor people in many,countries receive lower-quality ... can be done to change this pattern? Some strategies ... improving health,coverage of the poor, or soliciting poor clients, ... On July 15 at 12:00 noon at the Wilson ...
... Line-up Drawn From Over 250 Entries, GENEVA, Switzerland, ... Chronicles, the first ever international documentary film,competition on cancer, ... winner Freeheld and many other remarkable films from 16 ... of over 250,entries from 40 countries., The festival ...
... Roxane Laboratories, Inc.,announced today the approval ... Morphine,Sulfate Tablets and Oral Solution CII by ... Morphine Sulfate CII is available in,15mg, 30mg ... strengths.,Roxane Laboratories, Morphine Sulfate tablets and oral ...
... Poland, July 14 Preliminary findings,from a ... of project,management, released today at the Project ... business and organizational,performance can be significantly improved ... study, "Researching the Value of Project Management," ...
... 4-fold increase in death, major complications , , MONDAY, ... levels after heart surgery is essential, whether one is ... , The British report, published in Circulation ... surgery patients is linked to a fourfold increase in ...
... Long-Term Care, GREENSBORO, N.C., July 14 ... it successfully completed its,Discovery-180 technology assessment and ... http://www.foxlearningsystems.com ), a leading e-learning,organization based in ... innovator,of the Real Life, Real Learning(TM) staff ...
Cached Medicine News:Health News:Improving Health Care for the World's Poor: Public Health Experts Suggest Future Steps at Wilson Center 2Health News:First International Cancer Film Festival Announces Finalists 2Health News:First International Cancer Film Festival Announces Finalists 3Health News:Roxane Laboratories, Inc. Announces the Approval of Morphine Sulfate Tablets and Oral Solution 2Health News:Study: Global Business Performance Significantly Improved Through Project Management 2Health News:Poor Blood Sugar Control After Heart Surgery Impacts Outcomes 2Health News:Fox Learning Systems Selects Prymak's Discovery-180(TM) Technology Assessment to Guide Search for New LMS 2Health News:Fox Learning Systems Selects Prymak's Discovery-180(TM) Technology Assessment to Guide Search for New LMS 3
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
Medicine Products: